No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
REGN250117C685000
- 12.00
- -6.50-35.14%
15min DelayClose Jan 14 16:00 ET
12.00High12.00Low
12.00Open18.50Pre Close1 Volume6 Open Interest685.00Strike Price1.20KTurnover46.48%IV0.89%PremiumJan 17, 2025Expiry Date5.87Intrinsic Value100Multiplier3DDays to Expiry6.13Extrinsic Value100Contract SizeAmericanOptions Type0.5921Delta0.0134Gamma46.68Leverage Ratio-2.1263Theta0.0320Rho27.64Eff Leverage0.2417Vega
Intraday
- 5D
- Daily
News
Regeneron Pharmaceuticals Shares Are Trading Lower After Citigroup Cut Its Price Target on the Stock From $895 to $795.
Could The Market Be Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Its Attractive Financial Prospects?
Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $950
Regeneron Pharma Is Maintained at Neutral by Citigroup
Regeneron Pharmaceuticals Analyst Ratings